Screened 2026-09-08 · the tape above runs as of 19:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
McKesson Corporation holds its Markup at $889.12. The statistical read favours the sellers, held for 13 days.
As held on the ledger · 2026-09-08
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 13 days
Price at the screen
$889.12
Valuation
23.82 trailing · 17.62 forward price to earnings
Values screen
PASS· score 86.8
Beta
0.31
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
9.83%
Below 33%
Interest-bearing debt is just 9.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
37.23%
Below 49%
Money owed to the company is 37.2% of assets, under the 49% limit.
Pass
Revenue purity
0.05%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OVERVALUED: it trades at roughly a 19% discount to our $1,055.19 fair value, 7.70% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 18.7% margin of safety to the base estimate.
Third-party analyst targets: 15 covering, consensus Buy. The average target sits +12% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Drug distributor runs on thin margins
Imagine the backroom logistics that keep every pharmacy shelf stocked and every hospital supplied with the right medicines on time. McKesson sits at the centre of that daily flow across the United States, shifting branded and generic drugs plus medical supplies through its four main segments.
We pass on the shares. The stock trades at 16.7 times forward earnings with revenue growing just 6 percent and a profit margin of only 1 percent. Our fair value sits above the current price yet the opportunity rating marks the name overvalued, and an unknown moat leaves little room for error.
Analysts see upside to 941 dollars on average, but low returns and limited growth already price in most of the positives. Currency moves and reimbursement changes remain live risks even though the ethical screen clears. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MCK trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-05Markup$838.75-0.3%Entry 11
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.3% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (15 analysts) rates it strong buy, with a mean price target of $950.
2026-08-05Markup$840.90+0.0%Entry 10
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (15 analysts) rates it strong buy, with a mean price target of $950. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-04Markup$840.90+0.0%Entry 9
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (15 analysts) rates it strong buy, with a mean price target of $950. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-03Markup$840.90+0.0%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (15 analysts) rates it strong buy, with a mean price target of $950. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-02Markup$840.90+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (15 analysts) rates it strong buy, with a mean price target of $950. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-01Markup$840.90+0.0%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (15 analysts) rates it strong buy, with a mean price target of $950. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-31Markup$840.90+0.0%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (15 analysts) rates it strong buy, with a mean price target of $950. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-30Markup · changed$840.90+8.4%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (15 analysts) rates it strong buy, with a mean price target of $950. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Distribution$775.66+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (15 analysts) rates it strong buy, with a mean price target of $950.
2026-07-03Distribution$775.66+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.